The Future of Treatment

The first of two parts on genetics, this session will give participants an introduction to genetics and genetic testing (including current NHS guidelines) for prostate cancer. This session will be led by Dr Ramsay Bowden, Clinical Geneticist at Addenbrooke’s Hospital and a Fellow of Jesus College, Cambridge and Beverley Speight, Principal Genetic Counsellor Addenbrooke’s Hospital.

The second part in our genetics webinar will look at screening and clinical trials for those at higher risk of developing prostate cancer. This session is led by Dr Jana McHugh, a Clinical Research Fellow in Oncogenetics at The Institute of Cancer Research and Honorary Senior Registrar in Clinical Oncology at the Royal Marsden Hospital NHS Foundation Trust.

This session is led by Professor Andrew Hughes, Professor of experimental cancer medicine team at The University of Manchester, and previously clinical head of the Manchester Experimental Cancer Medicine Centre, one of the largest Phase 1 units in the UK.

He will be joined by Dr Nigel Brookes, Director Translational Science at biotechnology company, CellCentric, which has a new drug in development called “CCS1477” which is for the treatment of patients with late stage prostate cancer. More information about CellCentric and CCS1477 can be found here.

This session is led by Professor Dan Brewer, Senior Lecturer in Medical Bioinformatics and Genomics at the Norwich Medical School, Dr Dan Woodcock, Senior Data Scientist at the Nuffield Department of Surgical Sciences and Professor David Wedge, Professor of Cancer Genomics and Data Science at the University of Manchester.

They will be joined by Dr Antony Rix, CEO of Lucida Medical, a company who is using AI and ML to make cancer screening accurate, accessible, cost-effective, and quick. Lucida Medical’s Pi™ (Prostate Intelligence™) software analyses MRI scans and clinical data to support clinicians to identify which patients need a biopsy, where to target biopsies, and how best to treat patients.